CoChat
Sign Up
Cited by 185Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsSexual function and dysfunction studies

The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.

Menopausal hot flushes and night sweats: where are we now?

Archer, D. F., Sturdee, D. W., Baber, R., de Villiers, T. J., Pines, A., Freedman, R. R., Gompel, A., Hickey, M., Hunter, M. S., Lobo, R. A., Lumsden, M. A., MacLennan, A. H., Maki, P., Palacios, S., Shah, D., Villaseca, P., Warren, M.·2011·Climacteric
DOI 10.3109/13697137.2011.608596
Open this paper in CoChat — free account

Abstract

OBJECTIVE: An overview of the current knowledge on the etiology and treatment of vasomotor symptoms in postmenopausal women. MATERIALS AND METHODS: Acknowledged experts in the field contributed a brief assessment of their areas of interest which were combined and edited into the final manuscript. RESULTS: Women around the world experience vasomotor symptoms as they enter and complete the menopause transition. Vasomotor symptoms, specifically hot flushes, are caused by a narrowing of the thermoneutral zone in the brain. This effect, although related to estrogen withdrawal, is most likely related to changes in central nervous system neurotransmitters. Peripheral vascular reactivity is also altered in symptomatic women. Estrogen replacement therapy is the most effective treatment for hot flushes. Of the other interventions investigated, selective serotonin and selective norepinephrine reuptake inhibitors and gabapentin show efficacy greater than placebo. Objective monitoring of hot flushes indicates a robust improvement with hormone replacement therapy but little to no change with placebo. These data suggest that the subjective assessment of responses to therapy for vasomotor symptom results in inaccurate data. Hot flushes have recently been associated with increased cardiovascular risks and a lower incidence of breast cancer, but these data require confirmation. CONCLUSIONS: Vasomotor symptoms are experienced by women of all ethnic groups. They are caused by changes in the central nervous system associated with estrogen withdrawal and are best treated with estrogen replacement therapy. Objective monitoring of hot flushes indicates that placebo has little to no effect on their improvement. Subjective assessments of hot flushes in clinical trials may be inaccurate based on objective measurement of the frequency of hot flushes. Based on preliminary reports, women experiencing hot flushes have an increased risk of cardiovascular disease and a reduced incidence of breast cancer.

Overview

Integrity signals

Registry

Crossref · 10.3109/13697137.2011.608596

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 12

  1. Freedman R, 1992, Themoregulation: The Pathophysiological Basis of Clinical Disorders, 6
  2. Freedman RR, 1990, Obstet Gynecol, 76, 573
  3. Sassarini J, 2011, Climacteric, 14, 87
  4. Quan N, 1991, Am J Physiol, 261, R378
  5. Quan N, 1992, Am J Physiol, 262, R407
  6. Hunter M, 2011, Menopause
  7. Erlik Y, 1982, Obstet Gynecol, 59, 403
  8. Norman RJ, 2000, Cochrane Database of Systematic Reviews (Online), CD001018
  9. Prior JC, 2010, Presented at ENDO
  10. 10.1200/JCO.2008.19.6253 · DOI
  11. Rada G, Cochrane Database of Systematic Reviews
  12. Ray D, 1993, Br J Hosp Med, 50, 594

Cited by

Sorted by citations

See all 185

Related

See all

Metadata

Authors
Archer, D. F., Sturdee, D. W., Baber, R., de Villiers, T. J., Pines, A., Freedman, R. R., Gompel, A., Hickey, M., Hunter, M. S., Lobo, R. A., Lumsden, M. A., MacLennan, A. H., Maki, P., Palacios, S., Shah, D., Villaseca, P., & Warren, M.
Affiliations
  • Eastern Virginia Medical School (US)
  • Solihull Hospital (GB)
  • The University of Sydney (AU)
  • Tel Aviv Sourasky Medical Center (IL)
  • Wayne State University (US)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Royal Women's Hospital (AU)
  • King's College London (GB)
  • University of Glasgow (GB)
  • The University of Adelaide (AU)
  • University of Illinois Chicago (US)
  • Instituto Palacios (ES)
  • Pontificia Universidad Católica de Chile (CL)
  • Columbia University (US)
ORCID
Venue
Climacteric
Publisher
Informa UK Limited
Published
2011-08-18
Volume
14
Issue
5
Pages
515-528
ISSN
  • 1369-7137 (ISSN-L)
  • 1473-0804
DOI
10.3109/13697137.2011.608596
OpenAlex
W2025638598
Cited by
185
References
131
Citations by year
2026: 6 · 2025: 11 · 2024: 8 · 2023: 11 · 2022: 12 · 2021: 9 · 2020: 11 · 2019: 16 · 2018: 16 · 2017: 12 · 2016: 18 · 2015: 13 · 2014: 15 · 2013: 18 · 2012: 8
FWCI
1.82
Type
journal article
Language
en
Open access
closed
Locations
  • Climacteric (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
Keywords
hot flashes, night sweats, vasomotor symptoms, menopause, perimenopause, estrogen withdrawal, thermoneutral zone, peripheral vascular reactivity, hormone replacement therapy, selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, gabapentin, cardiovascular risk, breast cancer risk
MeSH terms
Adult, Body Temperature Regulation, Brain, Breast Neoplasms, Cardiovascular Diseases, Estrogens, Female, Humans, Menopause, Middle Aged, Risk Factors, Sweating, Vasomotor System, Estrogen Replacement Therapy, Randomized Controlled Trials as Topic, Neurotransmitter Agents, Hot Flashes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review